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Abstract 
 Bovine viral diarrhea viruses (BVDV) are important pathogens of cattle globally. 
Vaccination is often used to control BVDV, but complete control requires detection and 
elimination of cattle persistently infected (PI) with BVDV. These cattle are infected with 
BVDV during gestation, become immunotolerant to their strain of BVDV, and shed large 
amounts of BVDV throughout their lives. Infections of immunocompetent cattle are 
transient and produce a variety of clinical signs ranging from unapparent to fatal disease. 
Cattle PI with BVDV are the reservoir of most transient BVDV infections. Surveillance 
strategies and diagnostic assays have been developed to identify herds exposed to BVDV 
and individuals that are PI with BVDV. Many of these strategies and assays are costly 
and inconvenient for producers and are subsequently underused. New surveillance 
strategies that fit into common production schemes as well as accurate diagnostic assays 
based on easily-attainable samples are necessary to improve adoption of BVDV control. 
The research presented in this paper outlines opportunities to simplify BVDV sampling 
and detect immune evidence of BVDV infections in the form of nasal antibody specific to 
BVDV. Specifically, nasal swab samples were found to be as sensitive as the standard ear 
notch sample used in current antigen capture ELISAs. Alternative skin samples can also 
be used as accurate diagnostic samples in antigen capture ELISAs provided the kit used 
for diagnosis has been validated to use those samples. Before any surveillance program 
based on antibody responses to a pathogen can be implemented, the concentration and 
duration of passive antibodies to the pathogen must first be established. Research 
presented in this dissertation demonstrates that antibody of all isotypes can be measured 
in the secretions associated with the nasal and oral cavities. There is also strong evidence 
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that passively acquired antibody is transferred transiently into mucosal secretions of the 
mouth and nose. Analysis of pathogen-specific data reveals that mucosal antibody 
profiles may prove to be a useful tool for detecting acquired immune responses in calves 
at a much younger age than is currently permitted by serum antibody analysis. A study 
designed to investigate the value of BVDV-specific nasal antibodies in calves showed 
calves with high levels of anti-BVDV nasal antibodies had decreased risk of respiratory 
disease compared to calves with low levels of anti-BVDV nasal antibodies. These nasal 
antibodies likely indicate development of a complete, mature immune response to BVDV 
because of the T-lymphocyte help and time required to produce nasal antibodies specific 
to BVDV. Overall, the research presented in this dissertation reveals opportunities to 
improve BVDV detection in the U.S., but more research is needed to validate these 
techniques and samples. 
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Chapter 1. Introduction and literature review 
 
Introduction 
 Bovine viral diarrhea viruses (BVDV) are economically important viruses of 
cattle worldwide [1]. Cattle can be affected by transient infections with BVDV that result 
in reproductive loss, immunosuppression, and co-infection with other pathogens [2]. 
Cattle congenitally infected with BVDV during the first trimester of pregnancy become 
persistently infected (PI) and serve as the reservoir for new infections [3]. Control of 
BVDV is based on removal of PI animals from herds to eliminate challenge and 
vaccination of susceptible animals to prevent transient and congenital infections [4]. 
Surveys of cattle producers in the United States have shown that most producers 
recognize BVDV as a significant problem for cattle production, but few are taking action 
to eliminate BVDV PI cattle [5]. In the same survey, producers reported a lack of return 
on investment as the primary disincentive for BVDV control. In its current form, 
detection of BVDV PI cattle requires individual sampling followed by assays that detect 
the virus. Implementation of individual testing programs requires substantial investment 
of money and labor.  
 The overall purpose of the research presented in this dissertation is to mitigate the 
impact of BVDV infections in cattle. Four specific research objectives are addressed in 
this dissertation. First, investigation of alternative sample types offers the potential to 
provide alternatives to those currently in use. Since proficiency testing and validation of 
diagnostic assays requires large amounts of positive and negative sample types, the 
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second objective was to evaluate a common assumption that all haired bovine skin can be 
used as a diagnostic specimen for antigen-based ELISAs. These two objectives were 
designed and implemented to provide a better understanding of how current BVDV 
antigen-based diagnostics can be applied. 
 The third and fourth objectives were designed to utilize a novel approach to 
measuring immune responses to BVDV. This approach was centered around the concept 
of quantifying antibodies specific to BVDV on easily accessible mucosal surfaces, 
particularly of the nose and mouth. The third objective was to quantify the transfer and 
duration of maternal antibodies to saliva and nasal secretions of neonatal calves. The 
fourth objective was to determine the impact of BVDV-specific nasal antibodies in calves 
exposed to BVDV in the field.  
 These four objectives outline the work necessary to expand the body of 
knowledge surrounding BVDV management. Improved detection strategies combined 
with greater knowledge of disease impact will provide tools and incentives for BVDV 
control. 
Dissertation Organization 
 This dissertation is organized into 6 chapters, including the introductory chapter 
and the conclusions. Chapters 2-5 and the literature review contained in chapter 1 are 
manuscripts that are either published in peer-reviewed journals or will be submitted for 
publication.  
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Literature Review: Using secretory IgA in nasal secretions to diagnose herds with 
persistently infected cattle 
The purpose of this review is to explore the use of Bovine viral diarrhea virus 
(BVDV)-specific nasal secretory immunoglobulin A (sIgA) as a method immune of 
surveillance that complements production practices in order to improve producer 
compliance with BVDV control. Bovine viral diarrhea viruses are a group of enveloped, 
single-strand RNA viruses. BVDVs are classified as members of the genus Pestivirus 
within the family Flaviviridae [2]. Two species of BVDV, BVDV1 and BVDV2, have 
been described [6] and can be divided further in to many subspecies [2]. This marked 
diversity can be attributed to high mutation rates found in single-strand RNA viruses [7].  
BVDV exists as one of two biotypes depending on effect in cultured cells: 
cytopathic (CP) or non-cytopathic (NCP) [8]. NCP is the predominant BVDV biotype 
isolated from clinical cases and is the biotype associated with persistent infections (PI). 
Persistent infections are unique to members of the Pestivirus family and occur as a result 
of congenital infection during development of fetal self-tolerance [3]. Cattle born PI are 
infected for life, shed large amounts of virus, and efficiently infect non-PI contact cattle 
[9]. CP viruses arise from mutations of NCP BVDV in PI cattle [10]. Super-infection of a 
NCP PI animal with CP BVDV results in fatal mucosal disease [11]. Low virulence CP 
BVDV isolates are commonly included in vaccines because of antigenic similarities with 
NCP isolates and because they are incapable of producing PI offspring in cattle 
vaccinated during pregnancy.  
BVDV infection results in a diverse array of clinical presentations. BVDV 
infections in immunocompetent cattle result in immune response and pathogen clearance. 
These infections are known as transient infections (TI). Transient infections usually result 
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in subclinical infections causing mild fever, transient leukopenia, and seroconversion 
[12]. More severe TIs with BVDV cause fever, anorexia, lethargy, alimentary tract 
ulceration, diarrhea, leukopenia, and lymphoid depletion [13, 14]. Infections with 
BVDV2 cause particularly severe disease, including pronounced leukopenia, lymphoid 
depletion, and thrombocytopenia [15]. Transient congenital BVDV infection causes early 
embryonic death, abortion, and malformations of infected fetuses [16]. BVDV infection 
has been associated with respiratory disease, both as a primary etiologic agent [17] and in 
synergistic combination with Bovine Respiratory Syncytial Virus [18], Bovine 
Herpesvirus-1 [19], Mannheimia haemolytica [20], and Mycoplasma bovis [21]. This 
enhanced disease is likely attributable to BVDV-induced immunosuppression [22-24]. 
BVDV related disease conditions cause significant economic damage. 
Reproductive losses and clinical illness result in losses ranging from $20-57 per dairy 
cow year
-1
 [1, 25]. Observational studies coupled with mathematical models designed to 
predict losses in beef cow-calf production reveal $15-72 loss per cow year
-1
 [26, 27]. 
Estimations of economic loss in feedlot production can reach $88 per animal exposed to a 
BVDV PI animal [28]. A majority of cow-calf producers in the U.S. recognize BVDV as 
a significant problem in the beef industry [5]. Despite the estimated economic losses and 
awareness associated with BVDV, only 4.2% of surveyed producers tested any calves for 
PI with BVDV in the three years preceding the survey [5]. Many factors influence 
producer decisions to diagnose and removed BVDV PI calves from their herds including 
perceived return on investment, negative results of previous tests, and labor costs.  
 Because producers view BVDV as a significant issue, vaccination is a commonly 
implemented control measure. While vaccination offers considerable protection from the 
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harmful effects of BVDV infection [29, 30], evidence of vaccine failure exists [31]. 
Removal of PI animals to control challenge is needed to adequately control BVDV 
infections. Programs aimed at controlling or eradicating BVDV use a variety of 
diagnostic techniques with or without vaccination [32]. In the U.S., where vaccination is 
common, BVDV diagnosis centers on agent detection. Specifically, 
immunohistochemistry and enzyme-linked immunosorbent assays target protein antigens 
of BVDV [33, 34] and reverse-transcriptase polymerase chain reaction targets highly 
conserved regions of the BVDV genome [35].  These assays are accurate [36, 37], but 
require individual testing of all at-risk animals as well as follow-up testing to rule out 
accidental diagnosis of TI. Individual and follow-up testing are expensive and negative 
results are common given the low prevalence of PI cattle [38]. This scenario, coupled 
with insidious damage associated with BVDV infections, often leads producers to 
perceive a poor return on investment in PI surveillance.  
 In areas where BVDV control has become organized, detection of immune 
responses to BVDV infections is used to limit whole-herd agent testing to herds with 
evidence of infection [39]. Detection of immune responses, usually BVDV-specific 
antibody, is advantageous in control programs for several reasons. First, antibodies 
against BVDV have been shown to cross-react with distantly related BVDV isolates as 
well as other Pestiviral species [40]. Antibody cross-reactivity allows detection of 
BVDVs that are not directly targeted by the diagnostic assay. Reports of false negative 
antigen assay results highlight the value of assays that detect antibody cross-reactivity 
[41]. Second, sentinel populations can be monitored for serum antibody responses to 
BVDV rather than all individuals in a herd [42]. These sentinel populations are usually 
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groups of unvaccinated, young animals that no longer have BVDV-specific maternal 
antibody and have had adequate opportunity to become exposed and seroconvert to 
BVDV. Sentinel surveillance allows diagnosis of circulating BVDV infections using a 
small percentage of the herd to provide evidence justifying whole-herd agent testing to 
detect PIs. The limitations of sentinel-based immune surveillance using serum antibodies 
are revealed by the selection criteria. The presence of maternal antibody prevents 
accurate designation of status, as does the development of serum antibody following 
vaccination [39]. One study demonstrated successful herd-level diagnosis by measuring 
pre-colostral, BVDV-specific, serum antibodies in dairy calves [43]. This study 
effectively negated the confounding influence of maternal antibody and vaccination by 
choosing gestating calves as the sentinel population. While this approach was successful, 
adoption is limited by the requirement of precolostral serum samples, a difficult task in 
extensively managed beef cattle. The fourth advantage of using immune surveillance to 
detect BVDV infections is the ability to use samples other than serum. Bulk tank milk 
samples can easily be screened for BVDV-specific antibody [44]. This strategy is 
particularly useful to monitor status in herds that are naïve and do not vaccinate [39]. 
However, naïve, unvaccinated herds are very uncommon in the U.S. Herds with PI 
exposure will maintain high levels of bulk milk antibodies as long as exposed animals 
remain in the herd, thereby limiting the utility of this strategy early in BVDV control 
efforts. 
 Currently, BVDV control in the U.S. is limited by producer compliance, 
economic factors, and limited availability of useful surveillance strategies that fit 
production practices. A method of BVDV surveillance is needed that removes these 
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limitations by providing a simple, cost-effective, production compatible method. The 
goal of BVDV control is to mitigate new infections through removal of the source, the PI 
bovine. Conclusive diagnosis of PI status will continue to rely on BVDV antigen or 
genome detection; however, use of immune surveillance can be used to limit individual 
animal testing to groups of animals with evidence of exposure.  
Secretory IgA holds promise as a means of diagnosing infections of the mucosal 
surface, as is the case with BVDV, because of the targeted, active process of sIgA 
production and action. Currently, specific information related to induction, production, 
and function of sIgA in the bovine nasal passages is scarce. In contrast, significant 
research has been published on this topic in regard to humans and laboratory animals and 
in particular, the gut associated lymphoid tissue of these species. While the current body 
of knowledge must be confirmed by experiments examining the lymphoid tissue 
associated with the upper respiratory tract of cattle, current understanding of mucosa-
associated immunity will be used to postulate the value of BVDV-specific sIgA 
surveillance. 
Mucosa-associated lymphoid tissue (MALT) can be observed on every major 
bovine mucosal surface including the respiratory, alimentary, and genitourinary tracts 
[45]. These aggregations of lymphoid tissue specialize in detection and response to 
antigens encountered on each respective mucosal surface. Although MALT tissues may 
be physically distant from one another, they are linked together as part of the common 
mucosal immune system (CMIS) [46]. The CMIS has been practically demonstrated in 
mice by measurement of sIgA responses in intestinal and genital tracts following 
intranasal immunization with Respiratory Synsytial Virus-containing immune stimulating 
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complexes [47]. Similarly, calves challenged with Bovine Respiratory Synsytial Virus by 
a combined intranasal and intratracheal route showed IgM and IgA responses in feces and 
saliva in addition to IgM and IgA in nasal secretions and lung lavage fluid [48]. 
Secretory IgA-producing plasma cells are activated in MALT tissues as a result of 
immune surveillance of mucosal surfaces. The process begins as specialized follicle-
associated epithelial cells, known as microfold cells (M-cells) transcytose luminal 
contents by clathrin-mediated endocytosis, fluid-phase pinocytosis, actin-dependent 
phagocytosis, and macropinocytotic engulfment [49]. Immediately deep to the M-cell, 
clonally expanded B-lymphocytes are thought to survey transcytosed antigens and 
present them on MHCII to adjacent T-lymphocytes [50]. In mice, B-lymphocytes that 
bind their cognate antigen have been shown to receive co-stimulatory and cytokine, 
namely TGF-β, IL-5, IL-6, and IL-10 help to induce proliferation and class switching to 
predominantly IgA-producing plasma cells [51]. These plasma cells leave the MALT in 
which they were activated and respond to homing signals that result in migration to 
mucosal lamina propria or to sites of mucosal inflammation [51]. 
Mature, IgA-producing plasma cells in murine lamina propria translate 
monomeric IgA in the Golgi apparatus and then assemble polymeric, J-chain-linked IgA 
during secretion into the interstitial space [52]. Polymeric IgA diffuses through interstitial 
fluid to arrive at the basolateral surface of mucosal epithelial cells. Bovine mucosal 
epithelial cells have been shown to express polymeric immunoglobulin receptors (pIgR) 
that specifically bind to the J-chain associated with polymeric IgA [53]. Polymeric 
immunoglobulin receptors facilitate endocytosis of polymeric Ig including IgA, 
translocation to the apical cell surface, and exocytosis onto the mucosal surface. On the 
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mucosal surface pIgR is cleaved to release secretory IgA, a complex protein composed of 
J-chain linked polymeric IgA bound to a remnant of pIgR known as secretory component 
(SC) [54]. In addition to its critical role in polymeric IgA transport to mucosal surfaces, 
SC minimizes proteolytic cleavage of sIgA on the mucosal surface [55] and binds to 
mucin in mucosal secretions allowing longer activity at the mucosal surface and 
promoting pathogen clearance via the mucociliary apparatus [56]. 
Immune surveillance using mucosal antibodies is already commonly practiced in 
other areas of human and veterinary diagnostics. Human oral fluids are routinely 
collected and assayed for the presence of anti-HIV antibodies as a screening technique to 
identify new HIV infections [57]. Similarly, oral fluids are collected from groups of pigs 
to track viral infections such as Porcine respiratory and reproductive syndrome virus  
and Porcine circovirus 2 [58, 59]. In oral fluid samples, sIgA is present in combination 
with other isotypes of antibodies including IgG and IgM. Each of these antibodies has 
been shown to arrive in oral fluid following intravenous administration [60]; however, in 
healthy tissue the majority of oral antibody is produced locally with the dominant isotype 
being IgA [61]. Antibodies of the IgG isotype are thought to arrive in the healthy oral 
cavity as part of a crevicular serum transudate from gingival pockets [62]. During 
episodes of mucosal inflammation, increased vascular permeability is likely to allow 
significant amounts of serum Ig to bathe mucosal surfaces. This concept is supported by 
evidence in rats that shows increased movement of IgG into exudates in inflamed air 
pouches [63]. While the presence of any pathogen-specific antibody may suffice as 
evidence of natural infection for many diseases, the complexity of BVDV control in the 
U.S. requires measurement of antibody that can only be attributable to natural infection. 
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Because of this constraint, any measurement of IgG in mucosal fluid may result in false 
positive surveillance results due to the presence of serum IgG attributable to maternal 
antibody transfer or parenteral vaccination.  
Secretory IgA offers unique opportunities for disease surveillance because of its 
biology in mammals. First, sIgA is likely to be produced on mucosal surfaces distant to 
the one exposed to BVDV because of the circulation of plasma cells through the CMIS to 
mucosal effector sites. While BVDV is most often acquired via the oronasal route, cattle 
can also become infected by exposure of genital mucosal surfaces [64]. Mucosal samples 
can be easily collected from mucosal surfaces of the head and nasal secretions contain 
high concentrations of sIgA compared to oral secretions [65]. Since BVDV immune 
surveillance would likely employ nasal secretion samples, plasma cell migration 
following genital exposure to BVDV may be detectable. Second, mucosal sIgA specific 
to BVDV may allow differentiation of vaccinated from naturally infected cattle. Previous 
research demonstrated that parenteral priming of cattle with live Bovine respiratory 
syncytial virus (BRSV) failed to induce mucosal antibody responses [48]. Currently, most 
BVDV vaccines are administered via the parenteral route. Little is known about the 
impact of route of exposure on mucosal sIgA production in cattle, but given similar 
behavior to BRSV, vaccinates would only have nasal sIgA if they had previously been 
mucosally infected with live BVDV. Third, animals PI with BVDV tend to cause 
infections and antibody production in large percentages of the population in which they 
are housed [9]. Because of the high rate of infections seen as a result of PI exposure, 
relatively few nasal samples would be required to diagnose herd exposure status with 
high confidence [66]. A fourth benefit of nasal sIgA testing is the ability to predict risk of 
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BVDV-related disease conditions based on demonstrated immunity. Significant 
protection from bovine respiratory disease has been shown to be significantly related to 
high levels of nasal antibody specific to BVDV [67]. 
While BVDV-specific sIgA may serve as a plausible herd screening method, 
several knowledge gaps must first be filled to validate the technique. First, mucosal 
immune responses following both parenteral and mucosal exposure to BVDV vaccines, 
either modified-live or inactivated, have not been described in the literature. This 
information is essential to the accuracy of any diagnostic assay developed to measure 
sIgA in nasal secretions of cattle as well as to the ability to differentiate between 
parenteral vaccinates and cattle naturally exposed to BVDV. Second, mucosal antibody 
responses are thought to be short-lived and research investigating the duration of nasal 
sIgA response to BVDV is necessary for effective implementation of nasal sIgA-based 
herd screening. [68]. Some long-lasting nasal sIgA responses have been documented in 
cattle [69] and studies in mice and rats have shown that long-lasting mucosal sIgA 
responses can be developed, especially with repeated delivery of antigen [70, 71]. While 
yet unproven, BVDV infection is likely to produce long-lasting nasal sIgA responses due 
to the chronic nature of exposure from PI animals. Third, epidemiologic parameters 
related to the prevalence of detectable sIgA responses in groups of cattle with PI animals, 
TI animals, and vaccinates are necessary to establish appropriate sample sizes for herd 
level screening. Based on previously cited serologic evidence, sIgA prevalence associated 
with PI animals is also likely to be high. Future studies will need to determine the 
prevalence of BVDV-specific sIgA as a result of PI exposure. 
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BVDV continues to infect cattle and inflict financial damage on producers. 
Development of new surveillance tools that fit current production schemes is an 
important step toward better control. Future research examining the impact of BVDV 
infection and vaccination on mucosal antibody production may provide the foundation 
necessary to develop these diagnostics.  
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Abstract 
Bovine viral diarrhea viruses are economically important pathogens of cattle. 
Most new infections are acquired from animals persistently infected with the virus. 
Surveillance programs rely on skin biopsies for detection of persistently infected (PI) 
cattle. The purpose of this study was to compare antigen capture enzyme-linked 
immunosorbent assay (ACE) testing results using different types of samples from PI 
animals. The intent was to determine comparative detection rates in types of samples that 
are frequently submitted to diagnostic laboratories for evaluation of cases of unknown 
etiology or samples that could be easily collected for Bovine viral diarrhea virus 
(BVDV) screening. Eight types of samples were collected from 40 PI animals. The 
sample types were ear notches, serum, nasal swabs, conjunctival swabs, oral swabs, rectal 
swabs, vaginal/preputial swabs, and a tail-skin fold biopsy. Each type of sample (n = 8) 
for each animal (n = 40) was evaluated with a commercial ACE kit. When using ACE, 
tail-skin fold and nasal swab samples were 100% sensitive compared to results using ear 
notches. Sensitivity using other samples was as follows: serum and vaginal/preputial 
swabs, 92%; conjunctival swabs, 64%; rectal swabs, 10%; and oral swabs, 8%. Testing of 
tail-skin fold biopsies, nasal swabs, and ear notch samples resulted in reliable results. In 
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contrast, other sample types were unreliable for diagnosis of persistent infection in 
calves. 
Introduction 
Exposure to Bovine viral diarrhea virus (BVDV; family Flaviviridae, genus 
Pestivirus) results in economically important diseases in cattle.
5,6
 Infection with BVDV 
results in both persistent (a result of in utero exposure) and acute (a result of postnatal 
exposure) infections.
4,7
 Although viral shedding from acutely infected animals has the 
potential to infect other animals, persistently infected (PI) animals can shed high levels of 
BVDV during their lifetimes and are thought to be the principal source of new infections. 
An important strategy for controlling the economic impact of BVDV is to test for and 
remove PI animals. Several testing strategies have been developed to identify BVDV-
infected animals, and more importantly, differentiate acutely infected animals from those 
that are persistently infected. Examples of these tests include virus isolation, polymerase 
chain reaction (PCR), and immunohistochemistry (IHC). Antigen capture enzyme-linked 
immunosorbent assay (ACE) has also been developed to detect viral antigen that is 
present in either tissues or serum. The ACE-based tests are robust, economical methods 
of identifying PI cattle and are the most rapid tests available to date.
2
 The purpose of the 
current study was to investigate the potential of other types of samples for identifying 
cattle persistently infected with BVDV. The intent was not to validate alternative samples 
for BVDV detection, but rather to determine diagnostic sensitivity of samples that are 
frequently submitted to diagnostic laboratories for evaluation of cases of unknown 
etiology (e.g., cases of respiratory disease outbreaks in cattle) or types of samples that 
could be easily collected for BVDV screening. 
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Materials and methods 
Eight types of samples were collected from 40 animals previously identified as 
persistently infected based on 2 positive ACE tests of ear notch samples collected at least 
10 days apart (OIE Manual of Diagnostic Tests and Vaccines for Animals Chapter 
2.10.6; www.oie.int/eng/normes/mmanual/A_00132.htm). Three animals were from a 
stocker operation in northeastern Oklahoma (Washington County) and 37 were from a 
stocker operation in south central Oklahoma (Pottawatomie County). All of the animals 
were segregated from other animals on each premise because of their BVDV infection 
status. The 8 types of samples collected were as follows: ear notch and caudal tail fold 
biopsies, serum, and swabs from the prepuce or vagina, nasal cavity, ocular conjunctiva, 
oral cavity, and rectum. Both the ear notch and caudal tail fold samples were obtained 
with a small ear notcher that was cleaned with dilute chlorhexidine solution and rinsed in 
clean water between each calf. Serum samples were obtained by collecting whole blood 
via jugular venipuncture. Vaginal and/or preputial, nasal, conjunctival, oral, and rectal 
swabs were obtained by placing a polyester-tipped plastic applicator
a
 in contact with the 
sampled mucosal surface and rotating the swab rapidly several times. In situations where 
bilateral sampling sites were available (conjunctival swab, nasal swab), only one side was 
sampled. 
After collection, swabs were immediately submerged in 1 ml of sterile phosphate 
buffered saline (PBS) and placed on ice. Ear notch and caudal tail fold samples were 
placed in dry tubes and held on ice for approximately 2 hr for transport to the laboratory. 
Both skin and swab samples were frozen at –20°C immediately upon arrival at the lab. 
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The blood collected from each animal was centrifuged at 750 × g for 20 min, and the 
serum was placed in sterile 15-ml tubes and frozen at –20°C. Twenty-four hours before 
testing, swab samples were thawed at 4°C. Twenty-four hours prior to testing, 2 ml of 
PBS was added to each ear notch and caudal tail fold samples. After addition of PBS, 
samples were held at 4°C until testing. Serum samples were thawed immediately prior to 
testing. 
A commercially available ACE test
b
 was used to evaluate the samples for the 
presence of BVDV E
rns
 (gp48) antigen.
9
 ACE testing was performed per manufacturer’s 
directions. Optical density (OD) readings were determined, and the presence or absence 
of BVDV antigen in each sample was determined by calculating the sample to positive 
(S/P) ratio for each sample per manufacturer’s directions. The calculation of the S/P ratio 
was determined using the following formula: 
S/P = (Sa – N)/(Po – N), 
where Sa is the sample OD, N is the mean OD of the negative control, and Po is the mean 
OD of the positive control. Guidelines provided with the kit state that an S/P ratio of less 
than 0.20 indicates a negative BVDV antigen status, while an S/P ratio greater than 0.39 
indicates a positive BVDV antigen status. Samples with S/P ratios between 0.20 and 0.39 
are graded as “suspect” for BVDV antigen. 
In addition to testing each type of sample by ACE, a second ear notch from each 
calf was submitted to the Iowa State University Veterinary Diagnostic Lab (Ames, Iowa) 
for BVDV IHC.
8
 Serum virus neutralization assays were completed using BVDV virus 
from the subgenotypes 1a, 1b, and 2a. The BVDV titers regressed against S/P ratios for 
each sample type were evaluated using a statistical analysis software package.
c
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Results 
Results from testing each sample type were compared to the ACE and IHC testing 
results for each of the ear notch samples. Of the 40 calves tested, 39 were positive by the 
ACE and 40 were positive by the IHC. Because this investigation is principally 
concerned with ACE, results will be expressed as sensitivity based on the assumption that 
calves detected as persistently infected by ACE are true positives (see Fig. 1). The ACE 
test results were 100% sensitive using tail biopsies and nasal swabs. The sensitivity of 
ACE was reduced for the other sample types. The ACE results were 92% sensitive for 
detecting BVDV using vaginal and/or preputial swabs and serum; 64% sensitive using 
conjunctival swabs; 10% sensitive using rectal swabs; and 8% sensitive using oral swabs. 
Average BVDV titers were linearly related to S/P ratio for rectal and nasal swabs. No 
significant relationship was shown between BVDV titer or any other sample type (see 
Table 1). 
Discussion 
Although the prevalence of BVDV PI animals in the general population in North 
America is less than 1%, studies have shown that 7% of animals dying from infectious 
diseases in feedlots are persistently infected.
3
 Further, mortality rates among PI animals 
are 10-fold higher than those observed in non-PI animals.
5
 Skin biopsies, serum, and 
buffy coat samples are the sample types most frequently collected for surveillance efforts, 
and commercial test kits have been developed based on testing of these sample types. 
However, collection of skin biopsies is invasive and can be potentially disfiguring. 
Further, skin biopsies, serum, and buffy coat samples these sample types are not always 
submitted in cases of disease outbreaks of unknown etiology. The purpose of the current 
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study was to investigate the potential benefit of other types of samples for identifying 
cattle persistently infected with BVDV. The sample types used in the present study were 
selected based on similarity to standard sample types (tail fold biopsy), accessibility 
(nasal, conjunctival, oral, rectal, and vaginal swabs), comparability (preputial swabs on 
males for comparison to vaginal swabs on females), and because samples could otherwise 
be submitted in respiratory outbreaks of unknown etiology (nasal swabs). 
The current study revealed that the test results of skin biopsies from the caudal tail 
fold and nasal swabs had a high sensitivity compared to the standard ear notch sample. In 
contrast, testing of vaginal, preputial, conjunctival, oral, and rectal swabs performed at 
unsatisfactory levels. While the exact reason for the diminished performance of the 
vaginal, preputial, conjunctival, oral, and rectal swabs is undetermined, it is suspected 
that magnitude of viral shedding and bacterial contamination can potentially play a major 
role in each of the cases. Oral and rectal swabs, both from sites with very high bacterial 
loads, performed very poorly compared with nasal swabs or ear notches. Vaginal, 
preputial, and conjunctival swabs were taken from sites that may have had lower levels of 
viral shedding than in other tissues. Simple linear regression of serum antibody titer 
versus S/P ratio for each sample type was done to determine if the presence of antibodies 
affected detection by ACE (see Table 1). Serum antibody titers against BVDV 
demonstrated a significant linear relationship with S/P ratios from nasal and rectal swab 
samples. While nasal samples remained sensitive despite decreasing S/P ratios with 
increasing titers, sensitivity associated with rectal swabs may be more affected by 
increased antibody titer. The presence of serum antibody titers did not significantly affect 
the S/P ratios of other tissues tested. Such observations require further investigation. It 
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should be noted, however, that inclusion of suspect animals substantially increased the 
sensitivity of several sample types. The result indicates that virus may be successfully 
detectable at a low level in sample types other than skin and nasal swabs. The use of 
nasal swab samples has several potential benefits. Nasal swabs are a commonly 
submitted sample type for screening for a number of respiratory pathogens. Because 
BVDV often plays a role in the development of respiratory disease, the ability to use one 
sample type for several different tests would be beneficial in terms of both time and 
economics. 
One animal in the current study tested positive by IHC but was negative by all 
forms of ACE. A previously published report describes a scenario in which 3 acutely 
infected calves tested positive at initial screening by ACE and by IHC.
1
 The calves 
remained IHC positive 90 days after initial test, but were negative by all other tests 
including ACE, PCR, and virus isolation. The results from the study indicate that some 
BVDV antigens may persist in skin tissues after ACE detection is no longer possible.
1
 
Such a scenario could explain the apparent discrepancy between ACE and IHC in the 
current study. 
As stated above, another advantage to different sample types is the ability to 
choose a non-disfiguring sample for testing show animals. A significant potential source 
of BVDV spread is possible if a PI animal is brought to a livestock show and 
commingled with many other animals. The risk is especially high if pregnant animals are 
present. Required testing prior to livestock showing events is becoming more common, 
but owners are frequently unwilling to have an ear notch collected because of the 
disfigurement of the ear. While the collection of a serum sample is not disfiguring, the 
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accuracy of testing serum samples, as determined in the present study, was lower than 
nasal swabs. A non-disfiguring, noninvasive, more accurate method of sampling, such as 
nasal swab sampling, would likely increase compliance with testing and reduce the 
transfer of BVDV at show events. 
Sources and manufacturers 
a. Puritan Medical Products Co. LLC, Guilford, ME. 
b. IDEXX Laboratories Inc., Westbrook, ME. 
c. SAS Institute Inc., Cary, NC. 
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Tables and figures 
Table 1. Comparison of affect of virus neutralizing titer on the sample to positive ratio of 
each sample type. 
Sample Slope P-value 
Conjunctival swab –0.0089 0.6553 
Ear notch –0.0041 0.8895 
Nasal swab –0.0833 0.0115* 
Oral swab –0.0058 0.4592 
Rectal swab –0.0378 <0.0001* 
Serum –0.0192 0.2217 
Tail biopsy –0.0173 0.4529 
Vaginal and/or preputial swab –0.0326 0.2895 
* Statistically significant at the p < 0.05 level. 
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Abstract 
Bovine viral diarrhea virus is a costly disease of cattle that can be controlled by 
vaccination, biosecurity, and removal of persistently infected cattle. Development and 
proficiency testing of assays to identify persistently infected cattle requires substantial 
quantities of known positive- and negative-sample material. The objective of this study 
was to determine what sections of bovine skin contained Bovine viral diarrhea virus 
antigen. Two commercially available antigen-capture enzyme-linked immunoassays were 
used to test subsamples representing the entire skin of 3 persistently infected calves. Both 
assays detected Bovine viral diarrhea virus antigen in the samples indicated for use by 
assay protocol. However, one assay identified all subsamples as positive, while the 
second assay identified 64.4% of subsamples as positive. These results show that use of 
samples other than those specified by the assay protocol must be validated for each 
individual assay. In this study, alternative sample sites and use of the entire hide for 
proficiency testing would be acceptable for only one of the assays tested. 
Introduction 
Bovine viral diarrhea virus (BVDV; family Flaviviridae, genus Pestivirus) is a 
costly disease of cattle in the United States and around the world.
2,3
 The main reservoirs 
of BVDV in cattle populations are cattle persistently infected (PI) with BVDV due to 
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early gestational exposure.
5
 Persistently infected calves continuously shed large amounts 
of BVDV. Testing and removing PI calves from herds is useful for controlling spread of 
BVDV and is economically beneficial. Currently, several diagnostic tests are available 
for detecting BVDV PI calves including antigen-capture enzyme-linked immunosorbent 
assays (ACEs), which detect antigen in skin and serum samples. Ear notch samples are 
frequently used for BVDV detection and have been used in the licensing of several tests. 
However, development and validation of ACEs requires substantial quantities of known 
positive and negative sample material and the amount of ear skin samples that can be 
harvested from 1 animal is limited. Further, it is desirable to develop panels of known 
samples to be used in laboratory proficiency testing. While it is commonly held that all 
haired skin from PI cattle contains BVDV antigen, very little work has been done on skin 
samples from locations other than ears. The purpose of the current study was to use 2 
different ACEs to characterize the availability of BVDV antigen present in the total hide 
of cattle and to determine if skin from various regions of the body is suitable for 
validation and proficiency testing. 
Materials and Methods 
Three 200–300 kg cross breed beef calves, determined to be persistently infected 
by ACE,
a,8
 were used in the present study. Each calf was humanely euthanized by ranch 
personnel according to ranch protocols. The entire hide was removed from each calf, 
including the hide on the head and legs down to the coronary bands. At the time of 
harvest, the hides were divided into nearly equal quarters by folding them in half front to 
back and cutting on the crease and then folding them in half side to side and cutting on 
the crease again. Each quarter was labeled with the calf’s ID and a description of the 
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quarter (FL, FR, RL, and RR indicating front left, front right, rear left, and rear right, 
respectively) by placing a labeled ear tag in the quarter. Each quarter was then placed in 
an individual bag and placed on ice for transport to the lab. Quarters were stored at –
20°C. 
Each quarter was sectioned into 10 cm × 10 cm squares starting at the corner of 
the quarter nearest the middle of the hide. Sectioning was done using a precut 10 cm × 10 
cm template and common utility knives. Each section was given a unique identifying 
code to facilitate reconstruction of data maps based on location for analysis. The code 
consisted of a 2 letter code to identify the quarter (previously mentioned), a number to 
identify the medial to lateral position, and a letter to identify the cranial/caudal location. 
Each section was subsampled using a 4-mm leather punch that removed a full thickness 
circular sample of skin. The punch was cleaned with alcohol and then rinsed with water 
between each sample. Each section of hide was placed in a resealable bag and stored at –
20°C. Two samples were collected from each section and placed in 1.5-ml 
microcentrifuge tubes. The tubes were also stored at –20°C prior to ELISA analysis. 
Samples from each skin section were analyzed for BVDV antigen using 2 
different commercial ACE kits (A
a
 and B
b
). One subsample from each section was used 
for each kit. Each kit was used according to the manufacturer’s protocol. Samples for 
assay A were soaked in phosphate buffered saline (PBS), and an aliquot of the PBS was 
assayed for the presence of E
rns
, a structural protein of BVDV.
8
 Samples for assay B were 
soaked in the extraction buffer provided by the manufacturer, and an aliquot of this buffer 
was assayed for the presence of NS2/3, a nonstructural protein of BVDV. Since multiple 
plates from each kit were used to analyze all samples, great care was taken to make sure 
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that each plate was treated exactly the same way. Incubation times, wash volumes, and 
procedure order were identical for each plate. Sample optical density (OD) was measured 
using a plate spectrophotometer. The sample-to-positive (S/P) ratio was calculated using 
the following equation. 
S/P = (sample OD – negative control OD)/(positive control OD – negative control 
OD) 
The OD values of assay B were standardized using percent positivity (PP) according to 
protocol instructions, and PP was calculated using the following equation. 
PP = (sample OD/positive control OD) × 100 
The S/P ratio and PP data were used to construct sample signal intensity maps based on 
hide location. 
Data from each kit type was analyzed with a statistical analysis software 
package.
c
 Frequency tables were constructed to show test results by quarter. Prior to 
analysis, S/P ratio and PP data were examined for normal distribution. If data were not 
distributed normally, log transformation was employed to achieve normal distribution. 
Because of variability seen in assay B results, an examination of the relationship between 
skin thickness and logPP was conducted. 
Results 
Assay A returned positive S/P ratios for samples from all sections from each calf. 
Assay B identified 360 (64.4%) of 618 sections as positive and 220 (35.6%) as negative. 
Table 1 shows positive and negative results by quarter for assay B. 
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The PP data from assay B were right skewed and were log transformed. The 
results of a linear regression of skin thickness with logPP demonstrated that no 
significant linear relationship was present. 
Discussion 
The data in the current study show that BVDV antigens are present throughout the 
skin of animals persistently infected with BVDV. In the case of assay A, all skin sections 
returned a positive result, and overall variation in S/P ratio did not result in erroneous test 
conclusions for any particular section. Results from assay B demonstrated substantial 
variability to the point of misclassifying 35.6% of the skin sections. It is important to note 
that all skin sections that included the ear were positive using both assays. Visual 
examination of maps of assay B results did not demonstrate a definitive pattern of 
positive and negative results. 
Reasons for the discrepancies between assays remain unknown. One major 
difference between the 2 assays is their detection target. Assay A targets the E
rns
 protein 
of BVDV. This protein is associated with the viral envelope and host cell membranes and 
appears to be readily released into extracellular fluid.
6,7
 Assay B targets an epitope of the 
NS2/3 protein, which has been reported as a successful ELISA target for use in 
identifying animals persistently infected with BVDV.
1
 The antibodies found in assay B 
have also been incorporated into a blocking ELISA as a means of capturing p80 to serve 
as a target antigen to measure antibodies resulting from BVDV infection.
4
 The NS2/3 
protein is localized within host cells and is not a structural component of the BVDV 
virion.
6
 Because of its location, NS2/3 requires more intensive extraction methods to 
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make it available for detection. This difference in antigen location and availability may 
explain some of the differences in response seen between the 2 assays. 
The differences in results between the 2 commercial ACE kits examined in the 
current study reveal the need to validate sample site for any particular BVDV antigen 
test. In the case of assay A, skin samples from any piece of haired skin were found to be 
adequate samples for PI status determination as well as proficiency testing. However, 
skin samples other than the ears returned highly variable results when using the assay B 
kit. This variability would make using any alternative samples for PI determination or 
proficiency testing unreliable. 
Overall, both tests identified the calves as BVDV positive when using the sample 
(ear notch) indicated for use by kit instructions. In the present study, assay A was a more 
robust test for identifying BVDV antigen in skin samples other than ear notches. The use 
of parts of hides or entire hides for proficiency sampling will still require validation of 
desired sample sources on an individual assay basis. 
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Tables 
Table 1. Number of Bovine viral diarrhea virus–positive and –negative sections for each 
cattle hide quarter along with the corresponding percentage for that quarter using the 
assay B kit. 
Quarter 
Total Calf 1 Calf 2 Calf 3 
Positive Negative Positive Negative Positive Negative Positive Negative 
Front left 77 (55) 62 (45) 28 (53) 25 (47) 30 (61) 19 (39) 19 (51) 18 (49) 
Front right 70 (50) 69 (50) 28 (51) 27 (49) 21 (53) 19 (48) 21 (48) 23 (52) 
Rear left 126 (75) 42 (25) 51 (84) 10 (16) 43 (78) 12 (22) 31 (55) 25 (45) 
Rear right 125 (73) 47 (27) 61 (94) 4 (6) 36 (71) 15 (29) 29 (56) 23 (44) 
* Numbers in parentheses are percentages. Assay B was manufactured by Prionics AG, 
Zurich, Switzerland. 
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Chapter 4. Quantification of maternal antibodies transferred to the mucosal surface 
of neonatal bovine calves 
Brian L. Vander Ley, Shaun H. Sweiger, James A. Roth, and Julia F. Ridpath 
 
Abstract 
Mucosal antibodies are an important defense mechanism against invading 
pathogens as well as an increasingly popular target for disease surveillance. Neonatal 
cattle receive passive antibodies following ingestion of colostrum. While some reports 
have shown the presence of colostral antibodies in mucosal secretions of young calves, 
the purpose of this study was to comprehensively document the transfer of colostral 
antibodies to saliva and nasal secretions of neonatal calves. Eight calves were enrolled in 
the study by observing parturition and removing the calf prior to colostrum ingestion. Pre 
and post colostral saliva and nasal secretions were collected and assayed for IgM, IgA, 
IgG1, and IgG2 as well was for IgA specific to Bovine viral diarrhea virus. This study 
demonstrates significant evidence of maternal antibody transfer to the oral and nasal 
mucosal surfaces of calves. IgA, the most abundant mucosal antibody isotype, 
demonstrated a clear pattern of transfer that could not reasonably be attributed to any 
other mechanism due to the time required by a calf to mount an IgA response. 
Additionally, pathogen-specific antibody profiles demonstrate that mucosal antibodies 
may serve as a useful tool for identifying acquired immune responses in cattle at a 
younger age than is permitted by serum antibody analysis. 
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Introduction 
Mucosal antibodies (MA) are an important component of protective immune 
responses to pathogens that gain access to hosts via a mucosal surface. MA protect hosts 
by trapping pathogens in the mucous layer, by binding pathogen attachment sites to 
prevent invasion and by neutralizing toxins [1]. Cattle are susceptible to a variety of 
pathogens that gain access via mucosal surfaces. Of these, respiratory pathogens are 
particularly detrimental to cattle production [2]. Immunoglobulin transfer from dam to 
offspring has been shown to protect neonatal calves from respiratory disease [3], and 
other reports have shown that maternal antibody is transferred to oral and nasal mucosal 
surfaces of neonatal ruminants [4-6]. However, these reports present differing 
conclusions regarding the major types of immunoglobulins that are transferred to oral and 
nasal mucosal surfaces of neonatal calves. A comprehensive understanding of transfer of 
MA in neonates is necessary to understand the nature of MA kinetics from birth and to 
implement management strategies that exploit protective and diagnostic opportunities 
afforded by measurement of MA. The research presented in this report elucidates the 
transfer of maternal antibody to oral and nasal mucosal surfaces of neonatal calves.  
Materials and Methods 
The animal methods used in this project were approved by the Iowa State 
University Institutional Animal Care and Use Committee. 
Eight Holstein calves (4 male, 4 female) born in a 24 hour period were enrolled in 
the study. Parturition was observed for each enrolled calf to insure that no colostrum 
ingestion occurred prior to initial sampling. Immediately following parturition, calves 
were removed from the dam, dried and identified using plastic ear tags with unique 
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numbers. A mucosal secretion collection device consisting of a modified 1 ml serologic 
pipette connected in series to a red top Vacutainer tube and then to a vacuum pump was 
used to collect mucosal fluid from both the oral and nasal mucosal surface of each calf. 
Ear notch samples and whole blood were also collected from each animal.  
Following initial sample collection, calves were processed according to farm 
protocol. Each animal received 1 gallon of colostrum from a pool of sufficient size to 
enable feeding of all 8 calves from the same pool. The colostrum was administered via an 
esophageal feeder. The umbilical stump of each calf was treated with an iodine solution. 
Each calf received a bolus containing immunoglobulin against Escherichia coli K99 and 
bovine coronavirus (First Defense) and a subcutaneous injection of anti-colostridial toxin 
serum of equine origin (Clostridium C and D antitoxin, Colorado Serum Company). All 
calf processing procedures listed were performed within an hour of birth.  
Saliva, nasal secretions, and whole blood samples were collected on day 0 and 
then again on days 2, 7, and 14. Samples were collected prior to the morning feeding to 
allow as much time as possible for milk replacer associated immunoglobulins to 
dissipate. Whole blood was allowed to clot and then was centrifuged for 20 minutes at 
1000 x g. Separated serum was decanted into storage tubes. All samples stored at -20ºC 
prior to analysis. 
All calves in the study were moved to individual calf housing within 12 hours of 
birth. Each calf stall consisted of a wire panel enclosure with straw bedding that allowed 
nose to nose contact with neighboring calves. Calf enclosures were part of a passively 
ventilated (curtain) barn and all study calves were housed in the same section of the barn. 
Throughout the trial, calves were fed 2 quarts of reconstituted powdered milk replacer 
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twice daily. Calves were also offered starter feed and water for the duration of their stay 
in individual housing.  
Nasal and oral samples were diluted with phosphate buffered saline containing 
1mM EDTA (PBS-EDTA) at a ratio of 1 part sample to 3 parts PBS-EDTA. An equal 
volume of dilute dithiothreitol (Sputolysin reagent) was added to each diluted sample. 
After vortexing, the samples were incubated at room temperature for 15 minutes followed 
by a 3 minute centrifugation step at 3000 x g. Processed samples were either used 
immediately or stored at -80ºC.  
Total isotype specific immunoglobulin assays were used to quantify antibody 
concentrations in each sample collected from the calves. ELISA kits (Bethyl 
Laboratories) were used to quantify IgA, IgG1, IgG2, and IgM according to the standard 
reference sample provided with the kit. Isotype-specific immunoglobulin concentrations 
were determined from the standard reference sample using a microplate reader and 
accompanying software (Molecular Devices Softmax Pro). Samples were diluted with 
recommended buffers so that resulting signals fell within the range of signals developed 
by the reference sample standard curve. 
BVDV-specific IgA was measured in serum, nasal secretions, and saliva using a 
BVDV type 1 antibody detection ELISA kit (Idexx). The BVDV antibody ELISA kit was 
modified by the addition of anti-bovine IgA antibody conjugated with HRP at a dilution 
of 1:40,000 (Bethyl Laboratories). The BVDV antibody ELISA was used according to kit 
instructions for all samples except that substrate incubation time was increased from 10 
minutes to 20 minutes at room temperature. Raw optical density (OD) results were 
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normalized by use of the following equation. Sample to positive ratio (S/P) = [(Sample 
OD-Negative Control OD)/(Positive Control OD-Negative Control OD)]. 
Descriptive statistics, plots, and tables were prepared using a spreadsheet program 
(Microsoft Excel). Isotype half-lives from D2 to D7 were calculated using the equation:  
T1/2=0.693/kelim where kelim=ln(peak concentration)-ln(low concentration)/time interval. 
Median half-life for each isotype was calculated to prevent undue bias attributable to 
outliers and is reported in the results. 
Data were assessed for homogenous variances and normal distribution using a 
statistics software package (SAS 9.2). If data was found to have heterogenous variance, 
log transformation was employed. All transformed data were transformed back to the 
original scale for presentation in the results. Data groups that were distributed normally 
were analyzed using ANOVA to determine overall significance and a Dunnett’s post hoc 
test to compare each antibody isotype concentration on D0 to D2, 7, and 14. Data with 
heterogenous variances that could not be corrected by log transformation was analyzed 
using the Kruskal-Wallis method to determine overall significance. In these cases, 
pairwise comparisons between D0 concentrations and D2, 7, and 14 concentrations were 
made using the Mann-Whitney sign-rank test. Statistical comparisons were classified as 
significantly different if resulting p-values were less than 0.05. 
Results 
Average immunoglobulin concentrations in nasal secretions, saliva, and serum are shown 
by isotype in figure 1. Results of statistical analysis are shown in table 1. Average IgA 
concentrations in nasal secretions, saliva, and serum increased following colostrum 
ingestion and were significantly higher than the baseline concentration recorded on D0. 
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At D7, average IgA concentration declined and was not significantly different than D0 
concentration in nasal secretions and saliva. In serum, average IgA concentration 
declined sharply but remained significantly higher than D0 IgA concentration. On D14, 
average nasal IgA concentration increased to a level above average serum IgA 
concentration.  
 Average IgG1 concentration was significantly higher on D2, 7, and 14 compared 
to D0 for nasal secretions, saliva, and serum. Average IgG1 concentrations follow a 
similar pattern over time characterized by a sharp increase following colostrum ingestion 
at D2 and then steady decline. Overall, IgG1 concentration was very high in serum and 
much lower in nasal secretions and saliva. 
 Average IgG2 concentration was significantly higher on D2, 7, and 14 in saliva 
and serum compared with D0 for saliva and serum, but never for nasal secretions. A very 
slight increase in IgG2 concentration in saliva and serum can be noted following 
colostrum ingestion. In contrast to overall serum IgG1 concentration on all days, serum 
IgG2 concentrations are very low.  
 Average IgM concentration was significantly higher on D2, 7, and 14 for saliva 
and serum, and nasal secretions when compared to D0. In contrast to nasal secretion and 
saliva IgA, IgG1, and IgG2; IgM concentrations rose steadily over the course of the study 
rather than peaking at D2. Serum IgM concentration followed a similar patter to serum 
IgG1. 
 Median half-lives of each isotype are presented in table 2.  
 BVDV-specific IgA results are presented in figure 2. Average S/P ratio for nasal 
secretion, saliva, and serum BVDV-specific IgA increased from D0 to D2 following 
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colostrum ingestion. Nasal BVDV-specific IgA levels plateaued from D2 until D7 and 
then increased sharply on D14. Nasal BVDV-specific IgA S/P ratios were significantly 
higher on D2, 7, and 14 compared with D0. Both oral and serum BVDV-specific IgA S/P 
ratios declined from D2 to D7 and 14. Serum, but not oral, S/P ratios remained 
significantly different on D7 and 14 compared with D0.  
Discussion 
Antibodies arrive on mucosal surfaces of adult cattle as the result of either active 
transport or passive diffusion. IgA and IgM have been shown to reach mucosal surfaces 
by receptor mediated transfer. This process is characterized by local production of J-
chain linked IgA and IgM polymers by plasma cells in the lamina propria of the mucosal 
surface [7-9], followed by selective transfer of these polymeric antibodies to the mucosal 
surface by polymeric immunoglobulin receptor [10, 11]. Alternatively, some antibodies 
reach mucosal surfaces by passive diffusion of serum proteins. [9]. Antibodies of the 
IgG1 isotype are thought to arrive in the healthy oral cavity as part of a crevicular serum 
transudate from gingival pockets [12].  
The bovine uterine environment prevents exposure and therefor immunologic 
response to most antigens. This fact coupled with epitheliochorial placentation that 
prevents transfer of maternal immunoglobulins to fetal circulation results in very low 
concentrations of antibodies immediately post parturition. Ingestion of antibody-rich 
colostrum soon after birth leads to absorption of antibodies into the bloodstream. 
Previous research has indicated that some of these circulating antibodies arrive on 
mucosal surfaces [4-6].  
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In this study, transfer of colostral antibodies to circulation was evident. On D0 
(precolostral sample), all calves had very low levels of each antibody isotype in serum 
and by D2, all isotypes had increased significantly. Median half-lives for serum antibody 
isotypes were comparable to previously published estimates with the notable exception 
being IgG2 having a median 22.17 day half-life, compared with a previous estimate of 32 
days [13]. This finding may be attributable to very lows levels of transfer to serum and 
loss in mucosal secretions, particularly saliva. 
All antibody isotypes were measured at low levels in nasal secretions in the 
precolostral sample. Following colostrum ingestion, IgA, IgG1, and IgM concentrations 
all increased significantly by D2. While IgG1and IgM concentrations remained 
signficanly higher than those found in the precolostral nasal secretion sample, IgA 
concentrations declined by D7 and then began to increase again on D14, likely as a result 
of antigenic exposure and response. The mechanism by which IgG1 is transferred to nasal 
secretions of cattle has not been described, but the IgG1 found on nasal surfaces on D2 
can only be attributed to transfer from serum rather than endogenous production 
following antigenic stimulation. Continuous transfer of serum IgG1 from a robust serum 
IgG1 pool to nasal secretions coupled with onset of endogenous IgG1 production are 
likely to account for maintenance of IgG1 concentrations in nasal secretions after D7. 
Nasal secretion IgM follows a slightly different pattern, characterized by steadily 
increasing concentrations rather than a peak at D2 followed by a period of decline. IgM is 
the first antibody isotype that can be detected during an immune response [1]. Peeters et 
al.  demonstrated serum and fecal IgM production in neonatal calves 5 days after 
exposure to Cryptosporidium parvum [14]. In contrast, IgA and IgG production did not 
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begin to increase significantly until after 7 days post infection. In the case of nasal IgM, 
concentrations rose significantly above pre-colostral levels by day 2, suggesting the 
possibility of maternal transfer followed by initiation of endogenous IgM production. The 
hypothesis that endogenous IgM production begins early is further validated by the fact 
that IgM levels increased steadily for the duration of the experiment. Antibody 
concentrations in saliva followed a similar pattern to that seen with nasal antibody, albeit 
at lower levels.  
Generally, median half-lives of nasal secretion antibodies were very short. 
Mucosal surfaces are protected in part by the flushing action achieved by rapid 
production and removal of mucosal fluids, e.g. the mucociliary apparatus [15]. This 
flushing action removes antibodies as well, resulting in a short half-life. The median half-
lives of IgM, IgG1, and IgG2 in saliva were all negative in this study. These numbers 
reflect increasing antibody concentrations over time. Since all half-life calculations were 
completed based on D2 as the highest concentration and either D7 or 14 as the lowest 
concentration, a negative median half-life suggests that some animals had increased oral 
IgM, IgG1, and IgG2 during the calculation interval. In the case of IgM, endogenous 
production best explains increasing concentrations in this study. However, endogenous 
IgG1 and IgG2 production is very unlikely by D7 and may be slightly evident by D14. 
IgG1 in particular has been shown to leak into saliva via capillary leakage from the 
gingival sulcus [12]. Because of this leakage, continuous leakage of IgG1 into saliva may 
explain slight increases in concentrations and negative half-lives. Overall low levels of 
IgG2 make explanation of half-live difficult, but IgG2 may behave in a manner similar to 
IgG1. 
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BVDV-specific IgA was detected in nasal secretions, saliva, and serum. In nasal 
secretions, a small but significant transfer was seen prior to initiation of BVDV-specific 
IgA production after D7. BVDV-specific IgA production may be the result of exposure to 
BVDV. The infection status of the other calves co-housed with study calves was 
unknown. Since nose-to-nose contact was possible, study calves may have been exposed 
to BVDV very soon after birth. A slight, brief transfer of BVDV-specific IgA was noted 
in saliva, but the magnitude of transfer was much lower when compared to nasal 
secretions.  
This study demonstrates significant evidence of maternal antibody transfer to the 
oral and nasal mucosal surfaces of calves. IgA, the most abundant mucosal antibody 
isotype, demonstrated a clear pattern of transfer that could not reasonably be attributed to 
any other mechanism due to the time required by a calf to mount an IgA response. 
Reports have shown that a minimum of 7 days is required to produce a mucosal IgA 
response to intranasal challenge [6, 16]. These findings taken together with the 
observation in the present study of significantly increased levels of total IgA by day 2 
demonstrated the antibody was almost certainly of maternal origin.  
Mucosal fluids are being used as respiratory pathogen diagnostic and research 
samples in several species [17-19]. Because mucosal antibodies have been shown to be 
important in both mitigating disease and pathogen surveillance, a thorough understanding 
of their origin and kinetics is necessary to appropriately apply and interpret mucosal 
antibody detection assays. Historically, serum antibody responses have been used as a 
common method of measuring an immune response. These immune responses are used as 
research outcome variables and as a means of surveying populations for exposure to 
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disease. Long lasting maternal antibodies confound the use of serum antibody as a tool 
for these purposes. The work of Brennan, Litt, and Prickett et al shows that mucosal 
antibodies can be used in research and diagnostic endeavors, but the impact of passively 
acquired antibodies on mucosal surfaces must be characterized prior to implementing 
similar techniques in cattle. This research demonstrates that antibody of all isotypes can 
be measured in the secretions associated with the nasal and oral cavities. There is strong 
evidence that passively acquired antibody is transferred transiently into mucosal 
secretions of the mouth and nose. Analysis of pathogen-specific data reveals that mucosal 
antibody profiles may prove to be a useful tool for detecting acquired immune responses 
in calves at a much younger age than is currently permitted by serum antibody analysis. 
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Tables and figures 
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Analysis P P N P P P P P N N N N 
D0vsD2 S S S S S S NS S S S NS S 
D0vsD7 NS NS S S S S NS S S S S S 
D0vsD14 S NS S S S S NS S S S S S 
 
Table 1 shows results of statistical analysis for total Ig class concentration in nasal, oral, 
and serum samples. Analysis type is represented by P for parametric (Dunnett’s post hoc 
comparisons) and by N for nonparametric (Mann-Whitney pairwise comparisons). S = 
Significant; NS = Not Significant 
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Table 2 
Isotype Nasal Secretions Saliva Serum 
IgA 
(Range) 
2.4 
(
-
3858.3-5.4) 
6.3 
(4.3-71.2) 
2.9 
(2.6-3.2) 
IgM 
(Range) 
1.0 
(
-
16.5-109.6) 
-4.1 
(
-
24.2-
-
2.1) 
8.6 
(6.1-15.3) 
IgG1 
(Range) 
6.6 
(
-
17.8-17) 
-0.7 
(
-
27.3-29.2) 
20.9 
(15.1-44.2) 
IgG2 
(Range) 
4.0 
(
-
47.0-8.6) 
-0.2 
(
-
10.0-19.7) 
22.2 
(18.1-27.6) 
Table 2 shows median half-life (days) and range of half-lives for each antibody isotype in 
nasal secretions, saliva, and serum.  
 
Figure 1 
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Figure 2  
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Chapter 5. Impact of Bovine viral diarrhea virus-specific nasal antibody on 
morbidity and performance of high risk stocker cattle. 
A paper to be submitted to The Journal of Animal Science 
 
Brian L. Vander Ley, Douglas T. Ensley, Fred Lehman, Craig A. Jones, James A. Roth, 
Julia F. Ridpath, and Shaun H. Sweiger 
 
Abstract 
Bovine respiratory disease (BRD) is an economically significant problem 
impacting all areas of cattle production. The first objective of this research was to 
measure associations between Bovine viral diarrhea virus (BVDV)-specific nasal and 
serum antibodies, castration, arrival body weight, and arrival rectal temperature with 
BRD and average daily gain (ADG). A second objective was to measure the effect of 
vaccination with either modified live virus or killed virus BVDV vaccine on BRD and 
ADG. Calves were randomly assigned to either MLV or KV groups at enrollment. Intact 
male cattle were castrated. Rectal temperature and body weight were measured at 
enrollment. Body weight was measured again on days (D) 14, 28, and 44 of the study. 
Serum and nasal fluid samples were collected for BVDV-specific antibody analysis on 
days 0, 14, 28, and 44. Serum and nasal fluid BVDV-specific antibodies were measured 
using a commercial ELISA. Calves with D0 nasal antibodies (NA) levels below the 50
th
 
percentile had 2.26 times the odds of developing BRD compared with calves in the upper 
50
th 
percentile (p<0.0001). Calves that were castrated on arrival had 2.41 times the odds 
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of developing BRD compared with animals that were castrated prior to arrival 
(p<0.0001). Calves below the 50
th
 weight percentile had 1.52 times the odds of 
developing BRD compared to calves above the 50
th
 weight percentile (p=0.0217). No 
significant association between arrival rectal temperature and BRD was discovered in this 
study. Animals castrated prior to arrival had a 0.52 kg improvement in ADG compared 
with animals castrated on arrival (p<0.0001). A negative linear association was detected 
between arrival weight and ADG (Slope=-0.002, p=0.0259). A moderately significant 
positive linear association was present between D0 NA and ADG (slope=0.92, 
p=0.0852). The association between MLV or KV and BRD was not significant and was 
confounded by D0 NA. ADG was 0.15kg (p=0.0004) higher for calves in the MLV 
treated group compared to calves in the KV treated group. Several associations between 
easily-measured parameters and BRD were established. Some of these, namely castration 
and weight, have previously been studied. BVDV-specific NA offers a potential 
mechanism to quantitatively assign newly arrived cattle to risk groups due to its strong 
association with BRD. 
Introduction 
Bovine respiratory disease (BRD) is detrimental to the welfare and productivity of 
cattle. Economic losses incurred due to BRD include treatment costs, mortality, and 
inefficient growth [1, 2]. Most beef cattle production in the U.S. takes place occurs in two 
or more production facilities. Usually, cow-calf producers raise newborn calves until 
weaning age and then move them to forage-based calf development operations (stockers) 
or to feedlots. BRD risk is highest during and following movement between operations 
because of exposure to pathogens in marketing facilities and stress related to management 
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procedures [3]. Management procedures that induce stress, and may reduce resistance to 
BRD, include weaning, castration for males, dehorning, and shipping. Many producers 
perform these procedures and vaccinate their calves prior to marketing as part of a 
practice generally known as preconditioning. Preconditioned calves are physically and 
immunologically better prepared to remain healthy through transitions to stocker or 
feedlot operations [3].  
Bovine viral diarrhea viruses (BVDV) have been shown as economically 
significant pathogens in the development of BRD [4]. BVDV is immunosuppressive, acts 
synergistically with other respiratory pathogens to enhance disease, and can cause 
primary lung damage [5-7]. Calves that arrive at a feedlot seropositive for BVDV 
antibodies have been shown to be less likely to develop BRD [8]. Because of these 
effects, BVDV is a common target of diagnostics and vaccination as part of 
preconditioning and on arrival at stocker and feedlot operations.  
While preconditioning is recognized as a successful BRD prevention strategy, 
many calves are marketed each year without the benefit of preconditioning. A survey 
conducted by the United States Department of Agriculture found that 60.6% of surveyed 
producers never vaccinated cattle prior to marketing 
(http://www.aphis.usda.gov/animal_health/nahms/beefcowcalf/downloads/beef0708/Beef
0708_is_CalfVacc.pdf accessed 10SEP2012). Management information, including 
information about preconditioning, is not efficiently transferred from seller to buyer in 
most marketing situations. This communication failure necessitates risk assessment of 
newly acquired cattle. Because there are few objective tools available for risk assessment, 
assessment is based on subjective parameters such as appearance, origin, and lot size. 
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Stocker and feedlot producers compensate for uncertainty in risk assessment by applying 
broad management strategies that mitigate the impact of BRD. Many stocker and feedlot 
producers mass medicate cattle determined to be at high risk of respiratory disease with 
parenteral or oral antimicrobials. Increased production costs and public scrutiny are 
making these strategies less appealing.  
Most cattle are often vaccinated soon after arrival at stocker and feedlot 
operations to provide protection against respiratory pathogens. Producers implement 
specific vaccination programs for many reasons including cost, efficacy, and safety. 
Many viral respiratory vaccines are currently available and generally include a 
combination of Bovine herpesevirus-1, Bovine viral diarrhea virus-1, Bovine viral 
diarrhea virus-2, Parainfluenza virus-3, and Bovine respiratory syncytial virus. Each 
agent can be present in the vaccine as either modified-live virus (MLV) or inactivated 
virus (also known as killed virus [KV]).  
BRD management would benefit from objective methods of risk assessment that 
would allow selection of the most efficacious control strategies. Measurement of 
pathogen-specific nasal antibody offers opportunities to assess immunity against 
important BRD-related pathogens and thereby provide a direct, quantitative assessment 
of risk. Reports of association between pathogen-specific nasal antibodies and BRD risk 
are not available in the current literature. The first objective of this study was to examine 
the association between arrival BVDV-specific nasal antibodies and BRD. Further, 
associations of several other variables including arrival BVDV-specific serum antibodies, 
arrival weight, arrival temperature, and arrival castration status with BRD were 
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examined. This report does not present a predictive model for BRD; rather it identifies 
several easily-measured parameters that could be included in a predictive model.  
The association of BVDV with BRD has led to widespread vaccination of cattle as they 
arrive at stocker and feedlot operations. Much debate surrounds the issue of vaccine type 
administered to high risk cattle. Some producers cite rapid induction of immunity as a 
reason to use MLV whereas other producers opt for the perceived safety of KV. A second 
objective of this study is to compare the impact of vaccinating high risk stocker cattle 
with a vaccine containing KV BVDV compared to a vaccine containing MLV BVDV.  
Materials and Methods 
The animals in this study were privately owned and managed according to 
accepted production practices. They were not subjected to any invasive or painful 
procedures as part of this research. In addition, humane euthanasia protocols were in 
place to prevent unnecessary animal suffering as a result of naturally occurring disease 
conditions. 
This study was organized as a randomized trial with animal caretakers blinded to 
experimental groups. Six-hundred and one intact and castrated male, crossbred calves 
ranging in size from 115 to 287 kg were acquired from a southwestern Missouri auction 
market. No history could be obtained regarding vaccination or management history of 
these cattle. Two-hundred ninety-three were enrolled on 15SEP10 and 308 were enrolled 
on 22SEP10. Prior to enrollment, all animals were rested with hay and water for at least 
12 hours after arriving at the ranch. The study location was located in northeastern 
Oklahoma.  
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During each enrollment day, calves were randomly assigned to receive either an 
adjuvanted MLV BVDV respiratory vaccine (Pyramid 5, Boehringer-Ingelheim 
Vetmedica, St. Joseph, MO) or an adjuvanted KV BVDV respiratory vaccine (Prism 5, 
Boehringer-Ingelheim Vetmedica, St. Joseph, MO) using prepared randomization 
schedules. Separate randomization schedules for bulls and steers were utilized to prevent 
unnecessary bias due to castration stress. In addition to the BVDV component, both 
vaccines also contained MLV Bovine herpesvirus 1, Parainfluenza virus type 3, and 
Bovine respiratory syncytial virus. All animals were revaccinated at day 14 of the study 
with the MLV respiratory vaccine. 
Once assigned to a group, each calf received its allocated vaccination, an 
anthelminthic (Cydectin Injectable, Boehringer-Ingelheim Vetmedica, St. Joseph, MO), 
metaphylaxis (Excede, Pfizer Animal Health, Kalamazoo, MI), a Mannheimia 
haemolytica vaccine (Presponse SQ, Boehringer-Ingelheim Vetmedica, St. Joseph, MO), 
an 8-way clostridial vaccine (Covexin 8, Merck Animal Health, Summit, NJ), and two 
unique ear tags. Bulls were castrated via banding with the exception of sixteen bulls that 
required surgical castration due to poorly positioned testicles. Fifty-three calves had 
horns that were blunted by removing 2-3 cm of each horn (tipping). Ear notch samples 
were collected for BVDV PI testing (IDEXX Herdchek BVDV-Ag ELISA, Westbrook, 
ME). All events described were included in the study record for the appropriate group 
along with a description of each calf, initial rectal temperature, and initial weight.  
Animals with existing disease conditions at the time of enrollment were excluded 
from the study. Disease conditions included respiratory disease, lameness, bloat, or other 
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debilitating conditions that could bias to a particular research group. BVDV PI animals 
were removed within 24 hours of induction.  
Throughout the trial health events were recorded. BRD was defined as any animal 
with a clinical illness score (CIS) >1 and a rectal temperature >104.0°F. CIS was defined 
as 0 for animals that did not appear ill, 1 for animals that appeared mildly ill, 2 for 
animals that were moderately ill, 3 for animals that were severely ill, and 4 for animals 
that were moribund. This scoring system was based on subjective assessment of animal 
status by the animal caretakers. Animals were given Baytril (Bayer Animal Health, 
Shawnee Mission, Kansas) for their first BRD event, Nuflor (Merck Animal Health, 
Summit, NJ) for their second BRD event, and Biomycin (Boehringer-Ingelheim 
Vetmedica, St. Joseph, MO) for their third event after which they were no longer eligible 
for treatment. At the time of each event, date, rectal temperature, and weight were 
recorded. All mortalities were necropsied and the results were recorded in the treatment 
record. 
Calves were housed on grass pastures and supplemented with a pelletized protein 
feed. See Table 1for ingredients and analysis. 
Nasal swabs and blood were collected from each calf at enrollment (D0) and on 
days 14, 28, and 44. Nasal swabs were collected by rotating a nylon flocked swab 
(Puritan Medical Products, Guilford, ME) in one or both nasal passages of each calf until 
the swab was saturated. The swab was then placed in a 1.5 ml microcentrifuge tube 
labeled with the calf’s ID. Blood was collected via caudal vein venapuncture using 
Vacutainer needles and 10 mL serum separator tubes (BD, Franklin Lakes, NJ). After 
collection, the tube was labeled with the calf’s ID. All samples were placed on ice for 
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transport to the laboratory. Nasal swabs were frozen for long term storage. Blood tubes 
were centrifuged at 1000 x g for 20 minutes at 22ºC and the serum was decanted into 5 
ml serum storage tubes and refrigerated.  
Nasal swab samples were processed by thawing and then adding 300 µl PBS with 
1 mM EDTA followed by 400 µl of prepared dithiothreitol (DTT) reagent (Sputolysin 
Reagent, EMD Millipore, Rockland, MA). The nasal samples, including the swab, were 
vortexed and incubated at room temperature (22ºC) for 15 minutes. After the incubation, 
the samples were centrifuged for 3 minutes at 3000 x g and supernatant removed for 
analysis.  
Nasal and serum samples were assayed for the presence of BVDV-specific 
antibodies by means of a commercially available ELISA kit (Svanova BVDV-Ab, 
Uppsala, Sweden). Nasal antibody detection was achieved by spiking the conjugate 
provided in the kit with 2 ul/plate (1:5,000 dilution) sheep anti-bovine IgA antibody 
(Bethyl Laboratories, Montgomery TX). Kit protocol was followed with the notable 
exceptions that positive and negative control serum were diluted 5-fold in PBS for use as 
controls in the nasal antibody assay and incubation time was extended from 10 minutes to 
20 minutes during the substrate color development step. Intra-assay and interassay 
coefficients of variations (CV) were calculated from sample to positive (S/P) ratio data 
for nasal antibody measurements and from percent positivity measurements for serum 
antibody measurements. The following equations were used to standardize ELISA 
results. 
BVDV specific nasal antibody S/P = (Sample OD-Negative control OD)/(Positive 
control OD-Negative control OD). 
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BVDV specific serum antibody PP = (Sample OD/Positive control OD)*100 
Descriptive analysis of variables and treatment success data were performed using 
Microsoft Excel. Categorical variables collected include respiratory disease (yes or no), 
treatment group (MLV or KV), castration status (bull or steer), dehorn (yes or no), and 
enrollment set (1 or 2). Continuous variables collected included arrival temperature, 
arrival weight, D14 weight, D28 weight, D44 weight, D0 nasal antibody (NA), D14 NA, 
D28 NA, D44 NA, D0 serum antibody (SA), D14 SA, D28 SA, and D44 SA. Average 
daily gain was calculated for each calf by subtracting D0 weight from D44 weight and 
dividing by 44. Average daily gain was calculated for all animals, including mortalities. 
Treatment success variables calculated from treatment records included treatment success 
risk, treatment failure risk, relapse risk, second relapse risk, and new episode risk. See 
Table 2 for category definitions. 
Statistical analyses were performed using SAS 9.2 (SAS Institute, Cary, NC), 
specifically the mixed models procedure and logistic regression procedure. All 
continuous variables were either categorized into biologically relevant groups (i.e. 
hyperthermia and normothermia for temperature data) or were categorized into high and 
low observations corresponding to the upper and lower 50
th
 percentiles of observations. 
Morbidity data was analyzed using logistic regression with respiratory disease as the 
outcome variable of interest. For each model built, only one explanatory variable was 
designated as the explanatory variable of interest (i.e. a model for association of 
vaccination strategy and respiratory disease and a completely separate model for 
association of NA and respiratory disease). A univariate model containing only 
respiratory disease and the explanatory variable of interest was created to obtain an 
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unadjusted odds ratio (OR), then all relevant variables were added to create a full model. 
Interaction terms for enrollment set were evaluated at this stage. In the case of significant 
enrollment set interaction, a separate model for each enrollment set was generated. After 
an appropriate full model was built, variables with Wald type III p-values greater than 0.1 
were removed stepwise starting with the largest p-value. After each variable was 
removed, the OR for the explanatory variable of interest was assessed for significant 
change (>20%). If the change was greater than 20% when compared to the full model, the 
variable was forced back into the model as a confounding variable regardless of 
significance.  
Mixed models procedures were used to compare NA and SA terms at each time 
point. Each time point was analyzed for assumptions. In the case of non-normal 
distributions, observations were transformed by setting the lowest observation equal to 0 
and then adding the value needed to raise the lowest observation to 0 to all other 
observations. Adjusted observations were then natural log transformed . Estimates of 
means were back transformed and are presented in the results in their original form. In 
each analysis, vaccination group was the explanatory variable and enrollment set was 
included as a random variable to account for its influence on the relationship between 
vaccination and the measured/calculated variables. 
Results 
Of the 601 animals enrolled in the study, 583 animals with complete data sets 
were included in the final data analysis. Two animals were removed from the study at the 
time of enrollment, one due to recurrent bloat and the other due to existing chronic 
respiratory disease. Four animals, 1 from each pen of calves, were removed after being 
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diagnosed as a BVDV PI. Randomization successfully allocated 1 PI calf in each of the 4 
groups of calves, affording equal BVDV exposure opportunity across all groups. Four 
animals died during the study. Observations from mortalities were included in all 
applicable analysis, including ADG. Twelve animals were randomly selected for assay 
optimization; therefore, the observations from these animals were not included in the 
statistical analysis. Of the animals included in the statistical analysis, 53.7% were bulls, 
of which 16 required surgical castration. Fifty-three calves were dehorned. See Table 3 
for a summary of BRD by enrollment group.  
Intra-assay and interassay CV values for the nasal antibody ELISA were 2.3% 
and 2.6%, respectively. Intra-assay and interassay CV values for the serum antibody 
ELISA were 2.8% and 8.5%, respectively.  
Results of analysis of factors significantly associated with respiratory disease are 
presented in Table 4. Confounding analysis of the relationship between BRD and vaccine 
type by D0 nasal antibody revealed a change in OR of greater than 20%. Results of 
factors significantly associated with ADG are presented in Table 5. A plot of ADG by 
treatment group is shown in Figure 1. 
Discussion 
Serologic immunity against many respiratory pathogens, including BVDV, has 
been associated with decreased BRD morbidity in calves entering feedlot operations [8]. 
In field conditions, animals will have variable immune protection against BRD and 
information regarding vaccination or prior infection is often unavailable. This lack of 
information coupled with subjective risk assessment methods makes discernment of BRD 
risk in groups of cattle difficult.  
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Several reports of risk factors associated with BRD have been reported. 
Cernicchiaro measured associations of shrink, travel distance to the feedlot, and weather 
conditions with BRD [9-11]. Others have attempted to use biomarkers to predict BRD 
[12]. An inflammatory biomarker, haptoglobin, was shown to be unsuccessful as a 
predictor of BRD risk [13]. The etiology of BRD is complex and involves interactions of 
stress, pathogen and host immune response. Current predictive models lack easily-
measured variables related to immunologic protection against respiratory pathogens. At 
least one report has been published regarding the association between SA specific to 
several BRD pathogens and the incidence of BRD in the feedlot [8]. However, SA may 
not be an ideal representation of immune status due to the presence of waning colostral 
antibody [14, 15]. Since SA confounds detection of active immunity, both SA and NA 
levels were evaluated for potential impact on both BRD morbidity and ADG. Arrival SA 
was not found to be significantly associated with odds of BRD in this study. In contrast, 
high arrival NA levels specific to BVDV were associated with decreased odds of 
developing respiratory disease during the study. Similarly, serum antibody was not 
associated with ADG whereas arrival NA tended to be linearly related to ADG in a 
positive fashion.  
Previous research has shown that maternal antibody can be transferred to the nasal 
secretions of neonatal calves [16]. These antibodies usually persist for less than 3 weeks 
[17]. Pathogen-specific nasal antibodies found after 3 weeks of age can be attributed to 
endogenous active immune responses. Demonstration of a relationship between arrival 
NA specific to BVDV, a known contributor to BRD, and reduced respiratory disease 
reveals the impact of a complete, active immune response. In contrast, SA does not 
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appear to be as closely tied to BRD risk. Serum antibodies in calves of this age are 
present either as a result of maternal transfer or as a result of an endogenous, active 
immune response. This result may reflect the imperfect protection afforded by antibodies 
alone as opposed to the more complete immune response necessary to produce NA. The 
findings related to BVDV-specific NA on arrival confirm the association of active 
immunity with decreased odds of BRD. One explanation for the beneficial associations of 
BVDV-specific NA would be that an actively acquired immune response results in a 
more rapid control of BVDV infection. Previous research showed that calves vaccinated 
against BVDV and then challenged with highly virulent BVDV did not become viremic, 
had a reduced febrile response following challenge, and experienced less severe clinical 
disease compared to calves with no previous exposure to BVDV [18]. In the present 
study, BVDV-specific NA would be present as a result of a previous immune response. 
This response would result in both humoral and cell mediated immune defense 
mechanisms directed against a BVDV challenge [19].  
Vaccination against respiratory pathogens, including BVDV, is a common whole-
herd practice used by cattle producers to reduce respiratory disease losses. Producers can 
choose from a variety of vaccine types that include MLV, KV, and combinations of the 
two. MLV BVDV vaccines have been shown to cause changes in immune cell function, 
leading to concerns about immune suppression when combined with weaning and 
shipping stress [20]. While KV vaccines are thought to have fewer adverse effects, KV 
vaccination does not typically result in induction of cytotoxic T-lymphocytes [21]. These 
lymphocytes are stimulated following vaccination with MLV and are thought to be 
important for controlling BVDV infections [22]. In the present study, impact of vaccine 
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type on BRD was inconsistent between enrollment. Further statistical analysis showed 
that the association between vaccine type and BRD morbidity was confounded by D0 
NA. D0 NA satisfies the a priori criteria used to define a confounding variable [23].  
Producers are concerned about the production losses resulting from morbidity and 
mortality associated with BRD. Vaccination with a MLV was associated with higher 
ADG than was vaccination with KV. The difference in ADG may be attributable to better 
protection associated with MLV vaccination. Conversely, the difference in ADG may be 
associated with increased inflammation associated with the heavier antigen load in the 
KV vaccine.  
Overall, the significant association of BRD morbidity and NA specific to BVDV 
suggests a new metric that could be used in risk assessment of stocker cattle. More 
research needs to be done to validate the relationship between mucosal antibody and 
BRD.   
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Tables and figures 
Table 1 
Pellet Ingredient % of Formulation 
Wheat midds 25 
Corn gluten 25 
Soybean hulls 25 
Corn distiller’s grain 12.5 
Rice hulls 2.5 
Limestone 2.5 
Molasses 7.5 
  
Analysis 
Nutrient Composition (Dry Matter Basis) 
NEm MCal/CWT 77.41 
NEg MCal/CWT 60.43 
TDN % 73.34 
Crude protein % 14.69 
Fat % 3.73 
Crude fiber % 16.24 
ADF 22.43 
NDF 51.22 
eNDF 19.69 
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Table 2 
Therapy Response Variable Description 
Treatment Success An animal that is fully recovered following initial antibiotic 
therapy period, no additional therapy required within 21 
days of initial therapy. 
Treatment Failure An animal that at 72 hours post initial therapy, clinical 
illness score (CIS*) is greater than time 0 CIS or CIS is 1 
or greater and rectal temperature is >104.0º F. 
Relapse An animal that is deemed recovered at 72 hours post initial 
therapy but is observed with signs of BRD (CIS > 1) and 
has a rectal temperature > 104 F and is < 21 days from the 
initial therapy. 
Second Relapse An animal that contracts BRD within 21 days of second 
therapy. 
New Episode An animal that is observed with signs of BRD (CIS > 1) 
and has a rectal temperature > 104 F and necessitates 
treatment > 21 days following the previous therapy. 
Table 2 summarizes the definitions of therapy response variables.  
* CIS refers to clinical illness score which is a scale of 0-4 where 0 indicates no apparent 
illness, 1 indicates mild illness, 2 indicates moderate illness, 3 indicates severe illness, 
and 4 indicates a moribund state. CIS is a subjective measure of illness based on animal 
caretakers’ experience. 
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Table 3 Summary of health events by treatment group 
 MLV BVDV KV BVDV P 
Group Size 294 287 ND 
New BRD Events 98 102 0.7404 
BRD Relapses 37 43 0.4017 
Second BRD Relapse 10 10 0.9563 
BVDV PIs Removed 2 2 ND 
BRD Mortalities 2 1 ND 
Table 3 summarizes health events according to treatment group. 
Table 4 Factors significantly associated with new BRD events 
Variable Odds Ratio 
Estimate 
Lower 95% 
Confidence Limit 
Upper 95% 
Confidence Limit 
P-value 
Vaccine type divided by Enrollment group 
Enrollment Group1 
MLV Referent    
KV 1.89 1.11 3.18 0.0180 
Enrollment Group 2 
MLV Referent    
KV 0.55 0.33 0.93 0.0265 
Overall Analysis 
D0 Nasal Ab     
Low 2.26 1.57 3.25 <0.0001 
High Referent    
Castration 
Status 
    
Steer Referent    
Bull 2.41 1.68 3.47 <0.0001 
Weight     
<50
th
 Percentile 1.52 1.06 2.18 0.0217 
>50
th
 Percentile Referent    
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Table 5 Factors significantly associated with ADG 
Factor Estimate Lower 95% 
Confidence Limit 
Upper 95% 
Confidence Limit 
P-value 
MLV-KV* 0.15 kg 0.067 kg 0.23 kg 0.0004 
Steer-Bull* 0.5187 0.3423 0.6952 <0.0001 
D0 Nasal Ab  0.92§ -0.13 1.97 0.0852 
Weight -0.002§ -0.004 -0.0002 0.0259 
*Indicates the difference between two groups (i.e. KV group ADG subtracted from MLV 
group ADG. 
§Slope estimates for the linear relationship between the explanatory variable and ADG. 
Figure 1 
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Chapter 6. Conclusions 
 
Contributions to bovine viral diarrhea virus knowledge 
 The first objective for the research presented in this dissertation focused on 
evaluating alternative sample types for BVDV detection. Currently, a skin biopsy from 
the ear is the most common sample type. Other sample types that were evaluated include 
caudal tail fold biopsy, serum, nasal swab, conjunctival swab, vaginal preputial swab, 
oral swab, and rectal swab. When compared with ear notch ELISA, only caudal tail fold 
biopsy and nasal swabs correctly identified each persistently infected BVDV animal. 
Each of the other sample types incorrectly categorized positive animals as negative. This 
work is the first to describe a comprehensive evaluation of several sample types from 
known BVDV PI calves. The study did not include negative animals and therefore cannot 
predict the success of correctly categorizing negative animals with each sample type. 
Nasal swabs and caudal tail fold skin biopsies were shown to be accurate alternative 
samples for the identification of BVDV PI calves with the E
rns
 ELISA. 
 The second objective of this dissertation was to evaluate a common assumption 
that all haired bovine skin can be used as a diagnostic specimen for antigen based 
ELISAs. Two commercially available antigen capture ELISAs were evaluated a study to 
address this objective. The entire hide from 3 BVDV PI cattle was removed, 
subsectioned, subsampled, and assayed using an ELISA that detected the E
rns
 protein of 
BVDV and an ELISA that detected the NS2/3 protein of BVDV. This project 
demonstrated that the E
rns 
ELISA was able to identify all subsections of the 3 animals as 
positive, but the NS2/3 ELISA was only able to identify a portion of the subsections as 
positive. Overall, this study highlighted the individual performance of the two evaluated 
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assays. More importantly, this study demonstrated the need to validate samples prior 
before using them as positive controls, negative controls, or diagnostic samples for 
BVDV detection assays. 
 The third objective of this dissertation was to quantify the transfer and duration of 
maternal antibodies to the mucosal surface of neonatal calves. This objective was 
addressed by capturing pre-colostral and serial post-colostral saliva and nasal secretion 
samples. Total immunoglobulin isotype concentrations and BVDV-specific nasal IgA 
levels were measured from each of these samples. Overall, a clear, transient transfer of 
colostral antibody could be detected. This is critical information to future development of 
mucosal antibody diagnostic techniques. Currently, serum antibody diagnostic techniques 
are confounded by the presence of maternal antibody in young calves. A clear 
understanding of the kinetics of mucosal antibodies will enable development of 
diagnostic techniques that are not confounded by the presence of maternal antibodies. 
 The fourth objective was to determine the impact of BVDV specific mucosal 
antibody in calves exposed to BVDV in the field. The study presented in chapter 5 
addressed this objective by measuring BVDV specific nasal antibody in calves exposed 
to BVDV PI cattle. The animals enrolled in this study were stressed, highly commingled, 
auction market sourced animals that were at high risk of developing respiratory disease. 
Animals that had high levels of BVDV specific antibody were found to be at lower risk 
of developing respiratory disease compared to animals that had low levels of BVDV 
specific antibody. This finding is important because it demonstrates the importance of 
protection from BVDV in cattle that are at high risk of developing respiratory disease as 
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well as illustrating the potential damage of encountering BVDV without established 
protection.  
Future Research 
 Mucosal antibody responses to BVDV and many other respiratory pathogens have 
not been well characterized. The mucosal antibody response of different vaccine types 
and routes has been investigated for BRSV [1], but not for BVDV or other respiratory 
pathogens. Research in this area is important because prior research has shown that 
BRSV does not illicit the same response following its use in parenteral vaccines when 
compared with other common components of respiratory vaccines [2-4].  
 BVDV surveillance using antibody responses is not routinely used in the United 
States because of the prevalence of antibody response attributable to maternal antibody or 
vaccination. Controlled studies detailing the dynamics of BVDV mucosal antibody 
responses may offer potential surveillance techniques that are not affected by maternal 
antibody or vaccination. Research in other species has already demonstrated the value of 
mucosal antibodies for surveillance [5].  
 Bovine respiratory disease risk assessment is based on subjective information. 
The research presented in this dissertation shows a significant relationship between 
BVDV specific antibody and risk of respiratory disease in high risk stocker cattle. This 
information, if properly validated, could serve as an important step in developing 
quantitative risk assessment models for respiratory disease. More information about the 
kinetics of mucosal antibody responses to BVDV and other respiratory pathogens as well 
as information about other risk factors must be evaluated. 
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